446TiPREVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 29; no. suppl_8
Main Authors	Diab, A, Marcondes, M, Tagliaferri, M A, Hoch, U, Zhang, J, Rubas, W, Kivimae, S, Zalevsky, J, Conley, A P, Borazanci, E, D'Angelo, S P
Format	Journal Article
Language	English
Published	Oxford University Press 01.10.2018
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdy279.433